中国眼耳鼻喉科杂志2024,Vol.24Issue(6) :493-498.DOI:10.14166/j.issn.1671-2420.2024.06.011

阿司匹林脱敏及脱敏后维持口服治疗在阿司匹林加重的呼吸道疾病中的应用进展

Advances in aspirin desensitization and aspirin therapy after desensitization in aspirin-exacerbated respiratory disease

陈力嘉 冯影 明文华 王晓艳 王洪田 王学艳
中国眼耳鼻喉科杂志2024,Vol.24Issue(6) :493-498.DOI:10.14166/j.issn.1671-2420.2024.06.011

阿司匹林脱敏及脱敏后维持口服治疗在阿司匹林加重的呼吸道疾病中的应用进展

Advances in aspirin desensitization and aspirin therapy after desensitization in aspirin-exacerbated respiratory disease

陈力嘉 1冯影 2明文华 1王晓艳 1王洪田 1王学艳1
扫码查看

作者信息

  • 1. 首都医科大学附属北京世纪坛医院变态反应科 北京 100038;首都医科大学附属北京世纪坛医院变态反应中心 北京 100038
  • 2. 辽宁省辽阳市中心医院变态反应科 辽阳 111010
  • 折叠

摘要

阿司匹林加重的呼吸道疾病(AERD)是一种反复发作且治疗难度较大的疾病.目前,AERD患者的对症治疗方案以避免使用阿司匹林等非甾体类抗炎药物、标准药物治疗和手术治疗为主,新兴的生物制剂也为呼吸道症状管理提供了更丰富的手段.而阿司匹林脱敏治疗是AERD的唯一对因治疗方法.阿司匹林脱敏治疗后长期口服维持治疗是疗效维持的关键.本文就AERD的阿司匹林脱敏及脱敏后长期维持口服治疗的应用及进展进行综述.

Abstract

Aspirin-exacerbated respiratory disease (AERD) is a recurrent condition that poses significant management challenges. Currently,the primary treatment options for AERD include avoidance of aspirin and other nonsteroidal anti-inflammatory drugs,standard medical and surgical treatment. Several targeted biologics also provide new ways for managing respiratory symptoms. Aspirin desensitization is the only etiological treatment available for AERD. Ongoing aspirin therapy post-desensitization is crucial for maintaining therapeutic efficacy. This article reviews the application and advancements in aspirin desensitization as well as subsequent aspirin therapy in patients with AERD.

关键词

阿司匹林加重的呼吸道疾病/慢性鼻窦炎/哮喘/阿司匹林脱敏/阿司匹林脱敏后维持口服治疗

Key words

Aspirin-exacerbated respiratory disease/Chronic sinusitis/Asthma/Aspirin desensitization/Aspirin therapy after desensitization

引用本文复制引用

出版年

2024
中国眼耳鼻喉科杂志
复旦大学附属眼耳鼻喉科医院

中国眼耳鼻喉科杂志

CSTPCD
影响因子:0.555
ISSN:1671-2420
段落导航相关论文